MEDICLIN AG (MED.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:MED - DE0006595101 - Common Stock
3.38 EUR
+0.02 (+0.6%)
Overall MED gets a fundamental rating of 6 out of 10. We evaluated MED against 27 industry peers in the Health Care Providers & Services industry. While MED has a great profitability rating, there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on MED.
1. Profitability
1.1 Basic Checks
MED had positive earnings in the past year.
MED had a positive operating cash flow in the past year.
In multiple years MED reported negative net income over the last 5 years.
MED had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
MED's Return On Assets of 3.85% is fine compared to the rest of the industry. MED outperforms 66.67% of its industry peers.
MED has a Return On Equity of 14.15%. This is in the better half of the industry: MED outperforms 70.37% of its industry peers.
The Return On Invested Capital of MED (7.06%) is better than 66.67% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for MED is below the industry average of 6.91%.
The 3 year average ROIC (3.46%) for MED is below the current ROIC(7.06%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROIC | 7.06% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
1.3 Margins
MED has a better Profit Margin (4.40%) than 66.67% of its industry peers.
In the last couple of years the Profit Margin of MED has grown nicely.
With a decent Operating Margin value of 8.52%, MED is doing good in the industry, outperforming 70.37% of the companies in the same industry.
MED's Operating Margin has improved in the last couple of years.
MED has a Gross Margin of 84.08%. This is amongst the best in the industry. MED outperforms 88.89% of its industry peers.
MED's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% |
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
2. Health
2.1 Basic Checks
MED has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
The number of shares outstanding for MED remains at a similar level compared to 1 year ago.
MED has about the same amout of shares outstanding than it did 5 years ago.
The debt/assets ratio for MED has been reduced compared to a year ago.
2.2 Solvency
MED has an Altman-Z score of 1.58. This is a bad value and indicates that MED is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.58, MED is doing worse than 62.96% of the companies in the same industry.
MED has a debt to FCF ratio of 9.63. This is a negative value and a sign of low solvency as MED would need 9.63 years to pay back of all of its debts.
MED has a Debt to FCF ratio (9.63) which is comparable to the rest of the industry.
MED has a Debt/Equity ratio of 1.69. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.69, MED is doing worse than 70.37% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Altman-Z | 1.58 |
ROIC/WACC1.52
WACC4.64%
2.3 Liquidity
A Current Ratio of 1.93 indicates that MED should not have too much problems paying its short term obligations.
MED has a better Current ratio (1.93) than 85.19% of its industry peers.
A Quick Ratio of 1.89 indicates that MED should not have too much problems paying its short term obligations.
With an excellent Quick ratio value of 1.89, MED belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 |
3. Growth
3.1 Past
MED shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 414.18%, which is quite impressive.
The Earnings Per Share has been growing by 20.79% on average over the past years. This is a very strong growth
Looking at the last year, MED shows a small growth in Revenue. The Revenue has grown by 3.40% in the last year.
Measured over the past years, MED shows a small growth in Revenue. The Revenue has been growing by 2.19% on average per year.
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
3.2 Future
The Earnings Per Share is expected to grow by 13.85% on average over the next years. This is quite good.
The Revenue is expected to grow by 2.80% on average over the next years.
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 4.57, the valuation of MED can be described as very cheap.
Based on the Price/Earnings ratio, MED is valued cheaper than 100.00% of the companies in the same industry.
MED is valuated cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
The Price/Forward Earnings ratio is 6.26, which indicates a rather cheap valuation of MED.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MED indicates a rather cheap valuation: MED is cheaper than 100.00% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.12, MED is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.57 | ||
| Fwd PE | 6.26 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MED is valued cheaper than 96.30% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, MED is valued cheaply inside the industry as 92.59% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.45 | ||
| EV/EBITDA | 2.75 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of MED may justify a higher PE ratio.
MED's earnings are expected to grow with 13.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)0.22
EPS Next 2Y14.23%
EPS Next 3Y13.85%
5. Dividend
5.1 Amount
MED has a Yearly Dividend Yield of 1.16%. Purely for dividend investing, there may be better candidates out there.
MED's Dividend Yield is comparable with the industry average which is at 2.09.
With a Dividend Yield of 1.16, MED pays less dividend than the S&P500 average, which is at 2.41.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
DPN/A
EPS Next 2Y14.23%
EPS Next 3Y13.85%
FRA:MED (11/26/2025, 7:00:00 PM)
3.38
+0.02 (+0.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners1.54%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap160.55M
Revenue(TTM)797.34M
Net Income(TTM)35.05M
Analysts83.33
Price Target4.79 (41.72%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.16% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 4.57 | ||
| Fwd PE | 6.26 | ||
| P/S | 0.2 | ||
| P/FCF | 3.45 | ||
| P/OCF | 1.66 | ||
| P/B | 0.65 | ||
| P/tB | 0.72 | ||
| EV/EBITDA | 2.75 |
EPS(TTM)0.74
EY21.89%
EPS(NY)0.54
Fwd EY15.99%
FCF(TTM)0.98
FCFY28.96%
OCF(TTM)2.04
OCFY60.21%
SpS16.79
BVpS5.21
TBVpS4.7
PEG (NY)0.09
PEG (5Y)0.22
Graham Number9.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.85% | ||
| ROE | 14.15% | ||
| ROCE | 9.1% | ||
| ROIC | 7.06% | ||
| ROICexc | 9.61% | ||
| ROICexgc | 10.05% | ||
| OM | 8.52% | ||
| PM (TTM) | 4.4% | ||
| GM | 84.08% | ||
| FCFM | 5.83% |
ROA(3y)0.85%
ROA(5y)0.34%
ROE(3y)3.39%
ROE(5y)1.18%
ROIC(3y)3.46%
ROIC(5y)2.35%
ROICexc(3y)4.47%
ROICexc(5y)3.03%
ROICexgc(3y)4.72%
ROICexgc(5y)3.22%
ROCE(3y)4.46%
ROCE(5y)3.03%
ROICexgc growth 3Y64.29%
ROICexgc growth 5Y26.18%
ROICexc growth 3Y68.25%
ROICexc growth 5Y27.23%
OM growth 3Y67.11%
OM growth 5Y19.19%
PM growth 3Y148.06%
PM growth 5Y18.19%
GM growth 3Y0.37%
GM growth 5Y0.18%
F-Score8
Asset Turnover0.88
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.69 | ||
| Debt/FCF | 9.63 | ||
| Debt/EBITDA | 3.49 | ||
| Cap/Depr | 96.09% | ||
| Cap/Sales | 6.29% | ||
| Interest Coverage | 3.18 | ||
| Cash Conversion | 80.47% | ||
| Profit Quality | 132.66% | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.89 | ||
| Altman-Z | 1.58 |
F-Score8
WACC4.64%
ROIC/WACC1.52
Cap/Depr(3y)56.34%
Cap/Depr(5y)45.08%
Cap/Sales(3y)4.78%
Cap/Sales(5y)4.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)414.18%
EPS 3Y157.01%
EPS 5Y20.79%
EPS Q2Q%7.67%
EPS Next Y52.44%
EPS Next 2Y14.23%
EPS Next 3Y13.85%
EPS Next 5YN/A
Revenue 1Y (TTM)3.4%
Revenue growth 3Y3.65%
Revenue growth 5Y2.19%
Sales Q2Q%7.96%
Revenue Next Year4.55%
Revenue Next 2Y2.95%
Revenue Next 3Y2.8%
Revenue Next 5YN/A
EBIT growth 1Y281.51%
EBIT growth 3Y73.21%
EBIT growth 5Y21.8%
EBIT Next Year131.21%
EBIT Next 3Y31.07%
EBIT Next 5YN/A
FCF growth 1Y196.83%
FCF growth 3Y-17.96%
FCF growth 5Y7.78%
OCF growth 1Y96.85%
OCF growth 3Y-0.57%
OCF growth 5Y2.97%
MEDICLIN AG / MED.DE FAQ
What is the ChartMill fundamental rating of MEDICLIN AG (MED.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MED.DE.
What is the valuation status for MED stock?
ChartMill assigns a valuation rating of 9 / 10 to MEDICLIN AG (MED.DE). This can be considered as Undervalued.
What is the profitability of MED stock?
MEDICLIN AG (MED.DE) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MED stock?
The Price/Earnings (PE) ratio for MEDICLIN AG (MED.DE) is 4.57 and the Price/Book (PB) ratio is 0.65.
What is the earnings growth outlook for MEDICLIN AG?
The Earnings per Share (EPS) of MEDICLIN AG (MED.DE) is expected to grow by 52.44% in the next year.